Outcome MeasureQuality of Life

DS-II

Demoralization Scale – II

2 Papers in Blossom

Papers Using DS-II

Open Accessindividual

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study

This Phase I/II study (n=52) tested a group retreat model of psilocybin therapy for people with metastatic cancer and anxiety or depression, using 25 mg psilocybin in a 3-day retreat format. No unattended distress episodes occurred, and anxiety and depression scores fell over 28 days.

Published
Journal
Psychedelic Medicine
Authors
Back, A. L., McGregor, B. A., Thorn, L. L., Baker, K., Gooley, T., Kaelen, M., Harvey, K., Guy, J. M., Myers, S., Perez, J., Thompson, P., Billingsley, L., Sesnon, C.
Open Accessindividual

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial

This double-blind placebo-controlled trial (n=35) found that psilocybin-assisted psychotherapy (25mg) significantly reduced depression and anxiety symptoms in adults with life-threatening illnesses compared to an active placebo (100mg niacin), with benefits sustained at 26 weeks and improvements in spiritual well-being, quality of life, demoralisation, and death anxiety.

Published
Journal
General Hospital Psychiatry
Authors
Ross, M. L., Iyer, R., Williams, M. L., Boughey, M., O'callaghan, C., Hiscock, R., Dwyer, J.

Quick Facts

Full Name
Demoralization Scale – II
Domain
Quality of Life
Papers Indexed
2
Score Range
0–32
Interpretation
Lower = better
Unit
points
All Measures